These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Pharmacokinetics and pharmacodynamics of a nitric oxide-releasing derivative of enalapril in male beagles. Okuyama CE, Mendes GD, Faro R, Rezende VM, Lagos RM, Astigarraga RE, Antunes E, De Nucci G. Clin Exp Pharmacol Physiol; 2007 Apr; 34(4):290-5. PubMed ID: 17324140 [Abstract] [Full Text] [Related]
8. Pharmacokinetic and pharmacodynamic comparative study of zofenopril and enalapril in healthy volunteers. Marzo A, Dal Bo L, Mazzucchelli P, Monti NC, Crivelli F, Ismaili S, Giusti A, Uhr MR. Arzneimittelforschung; 2002 Apr; 52(4):233-42. PubMed ID: 12040965 [Abstract] [Full Text] [Related]
9. The clinical pharmacology of lisinopril. Case DE. J Hum Hypertens; 1989 Jun; 3 Suppl 1():127-31. PubMed ID: 2550635 [Abstract] [Full Text] [Related]
10. Comparison of the steady-state pharmacokinetics of fosinopril, lisinopril and enalapril in patients with chronic renal insufficiency. Sica DA, Cutler RE, Parmer RJ, Ford NF. Clin Pharmacokinet; 1991 May; 20(5):420-7. PubMed ID: 1652404 [Abstract] [Full Text] [Related]
11. Pharmacodynamics and population pharmacokinetics of enalapril and lisinopril. Ajayi AA, Campbell BC, Kelman AW, Howie C, Meredith PA, Reid JL. Int J Clin Pharmacol Res; 1985 May; 5(6):419-27. PubMed ID: 3005181 [Abstract] [Full Text] [Related]
12. A comparison of single doses of lisinopril and enalapril in hypertension. Dews I, Wiseman WT, al-Khawaja I, Stephens J, VandenBurg M. J Hum Hypertens; 1989 Jun; 3 Suppl 1():35-9. PubMed ID: 2550644 [Abstract] [Full Text] [Related]
13. The effects of age and renal impairment on the pharmacokinetics of co-administered lisinopril and hydrochlorothiazide. Laher MS, Mulkerrins E, Hosie J, Connell PA, Smith RP, Swaisland AJ. J Hum Hypertens; 1991 Dec; 5 Suppl 2():77-84. PubMed ID: 1665183 [Abstract] [Full Text] [Related]
14. Lisinopril and nifedipine: no acute interaction in normotensives. Lees KR, Reid JL. Br J Clin Pharmacol; 1988 Mar; 25(3):307-13. PubMed ID: 2833920 [Abstract] [Full Text] [Related]
15. A study of the potential pharmacokinetic interaction of lisinopril and digoxin in normal volunteers. Vandenburg MJ, Morris F, Marks C, Kelly JG, Dews IM, Stephens JD. Xenobiotica; 1988 Oct; 18(10):1179-84. PubMed ID: 2853897 [Abstract] [Full Text] [Related]
16. Characterization of the pharmacokinetic and pharmacodynamic properties of the angiotensin-converting enzyme inhibitor, enalapril, in horses. Gardner SY, Atkins CE, Sams RA, Schwabenton AB, Papich MG. J Vet Intern Med; 2004 Oct; 18(2):231-7. PubMed ID: 15058776 [Abstract] [Full Text] [Related]
17. Pharmacokinetic and pharmacodynamic actions of enalapril in humans: effect of probenecid pretreatment. Noormohamed FH, McNabb WR, Lant AF. J Pharmacol Exp Ther; 1990 Apr; 253(1):362-8. PubMed ID: 2158548 [Abstract] [Full Text] [Related]
18. Effects on plasma angiotensin-converting enzyme activity and circulating renin of lisinopril and enalapril alone and in combination with propranolol in healthy volunteers. Hansen EF, Bendtsen F, Henriksen JH. Pharmacol Toxicol; 1999 Mar; 84(3):110-4. PubMed ID: 10193670 [Abstract] [Full Text] [Related]
19. Review of studies on the clinical pharmacodynamics of cilazapril. Belz GG, Breithaupt K, Erb K. J Cardiovasc Pharmacol; 1994 Mar; 24 Suppl 2():S14-9. PubMed ID: 7898090 [Abstract] [Full Text] [Related]
20. Enalapril and lisinopril in renovascular hypertension--antihypertensive and hormonal effects of two new angiotensin-converting-enzyme (ACE) inhibitors. A preliminary report. Karlberg BE, Fyhrquist F, Grönhagen-Riska C, Tikkanen I, Ohman KP. Scand J Urol Nephrol Suppl; 1984 Mar; 79():103-6. PubMed ID: 6089307 [Abstract] [Full Text] [Related] Page: [Next] [New Search]